Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064497 | 0.91 | PDE4D (0.39) | PDE4DPDE4APDE4BPDE4CMEN1 | |
| SCHEMBL5066758 | 0.90 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CMEN1 | |
| SCHEMBL5067976 | 0.90 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CMEN1 | |
| SCHEMBL5483281 | 0.87 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5504906 | 0.84 | PDE4D (0.41) | PDE4DPDE4APDE4BPDE4CPDE3A | |
| SCHEMBL2264284 | 0.84 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CMEN1 | |
| SCHEMBL2264024 | 0.83 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4CPDE3A | |
| SCHEMBL5509736 | 0.83 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CMEN1 | |
| SCHEMBL5623979 | 0.83 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4CMEN1 | |
| SCHEMBL5621856 | 0.83 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161339-A1 | Novel Thio-Containing Hydroxy-6-Phenylphenanthridines and their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2008-07-03 | — | — | US | claimed |
| US-20080161339-A1 | Novel Thio-Containing Hydroxy-6-Phenylphenanthridines and their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161339-A1 | Novel Thio-Containing Hydroxy-6-Phenylphenanthridines and their Use as Pde4 Inhibitors | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.